Reaction
Astigmatism reporting signals
As of the last recalculation, Astigmatism appears in 1,492 FAERS reports alongside 26 co-occurring drug terms. The strongest observed disproportionality signal is VALPROATE SODIUM (PRR 54.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Valproate Sodium | 77 | 54.7 | 54.9 |
| Prednisolone Acetate | 28 | 38.5 | 38.6 |
| Phytonadione | 11 | 18.2 | 18.2 |
| Thiotepa | 11 | 16.2 | 16.2 |
| Valproic Acid | 31 | 14.0 | 14.0 |
| Atropine | 7 | 11.8 | 11.8 |
| Clindamycin | 22 | 11.0 | 11.0 |
| Meperidine Hydrochloride | 7 | 10.6 | 10.7 |
| Vigabatrin | 10 | 9.6 | 9.6 |
| Carboxymethylcellulose Sodium | 5 | 7.4 | 7.4 |
| Desoximetasone | 10 | 7.4 | 7.4 |
| Ribociclib | 16 | 7.1 | 7.1 |
| Vemurafenib | 6 | 7.0 | 7.0 |
| Ado-Trastuzumab Emtansine | 4 | 6.6 | 6.6 |
| Ranibizumab | 12 | 6.3 | 6.4 |
| Timolol | 5 | 5.8 | 5.8 |
| Belimumab | 13 | 5.8 | 5.8 |
| Brimonidine Tartrate | 7 | 5.5 | 5.5 |
| Faricimab | 3 | 5.2 | 5.2 |
| Canakinumab | 4 | 5.2 | 5.2 |
| Lumacaftor And Ivacaftor | 3 | 4.9 | 4.9 |
| Fingolimod Hcl | 29 | 4.8 | 4.8 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 4 | 4.5 | 4.5 |
| Encorafenib | 3 | 4.2 | 4.2 |
| Lifitegrast | 4 | 3.4 | 3.4 |
| Galcanezumab-Gnlm | 6 | 2.7 | 2.7 |